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Congenital insensitivity to pain with anhidrosis (CIPA) is a
rare autosomal recessive disorder characterized by insensitivity
to noxious stimuli and variable intellectual disability (ID) due to
mutations in theNTRK1gene encoding theNGF receptorTrkA.
To get an insight in the effect of NTRK1 mutations in the cog-
nitive phenotype we biochemically characterized three TrkA
mutations identified in children diagnosed of CIPA with vari-
able ID. Thesemutations are located in different domains of the
protein; L213P in the extracellular domain, 736 in the kinase
domain, and C300stop in the extracellular domain, a newmuta-
tion causing CIPA diagnosed in a Spanish teenager. We found
that TrkA mutations induce misfolding, retention in the endo-
plasmic reticulum (ER), and aggregation in a mutation-depen-
dentmanner. The distinctmutations are degradedwith a differ-
ent kinetics by different ER quality control mechanisms;
although C300stop is rapidly disposed by autophagy,736 deg-
radation is sensitive to the proteasome and to autophagy inhib-
itors, and L213P is a long-lived protein refractory to degrada-
tion. In addition L213P enhances the formation of autophagic
vesicles triggering an increase in the autophagic flux with dele-
terious consequences. Mouse cortical neurons expressing
L213P showed the accumulation of LC3-GFP positive puncta
and dystrophic neurites. Our data suggest that TrkAmisfolding
and aggregation induced by some CIPA mutations disrupt the
autophagy homeostasis causing neurodegeneration. We pro-
pose that distinct disease-causing mutations of TrkA generate
different levels of cell toxicity, which may provide an explana-
tion of the variable intellectual disability observed in CIPA
patients.
Congenital insensitivity to pain with anhidrosis (CIPA)5
(MIM number 256800), also known as hereditary sensory and
autonomic neuropathy type IV (HSAN-IV), is a rare autosomal
recessive disorder (1, 2). It is characterized by insensitivity to
noxious stimuli, recurrent hyperpyrexia related to high ambi-
ent temperature, inability to sweat (anhidrosis), self-mutilation
in the first months of life, and increased risk to bone fractures,
multiple scars, osteomyelitis, joint deformities, and limb ampu-
tation as children grow older (1, 3). Death from hyperpyrexia
occurs within the first 3 years of life in almost 20% of the
patients and most patients show intellectual disability (ID) of
varying severity.
Inactivatingmutations in the NTRK1 gene encoding TrkA, a
receptor tyrosine kinase for nerve growth factor (NGF), are
responsible of CIPA development (4). The survival of nocicep-
tive neurons and sympathetic ganglia derived from the neural
crest depends on NGF stimulation (5–7). NGF/TrkA signaling
is required not only for survival, but also for the sprouting and
differentiation of nociceptor neurons during development (6,
8). The altered perception of pain and temperature and anhi-
drosis in CIPA are due to the absence of unmyelinated C-fibers,
small-diameter myelinated A-fibers, and lack of sweat glands
innervations (1). In addition, CIPApatients present variable ID,
although the causes for this are still unknown, its variability
may indicate a mutation-specific phenotype.
To date, more than 50 TrkAmutations that cause CIPA have
been described (9). Mutations are distributed all along the pro-
tein sequence of TrkA, from the extracellular to the kinase
domain. Missense mutations usually affect the kinase domain
where they disturb the kinase activity of TrkA by inducing con-
formational changes or misfolding. There are, as well, several
nonsense mutations changing the open reading frame or intro-
ducing a stop codon. Although these mutations are clearly det-
rimental to the TrkA function, they generate truncated forms
that may impinge the protein homeostasis, proteostasis, of the
cell where they are expressed.
The folding of the secretory and the membrane proteins
takes place in the endoplasmic reticulum (ER). The quality of
the proteins folded in the ER is carefully monitored by an ER-
quality control mechanism, which allows only correctly folded
proteins to be transported to their final destinations (10–14).
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Misfolded and aggregated proteins are subsequently degraded
by different clearance pathways like “ER-associated degrada-
tion” (ERAD) (11, 13–15) or by autophagy (16, 17) or a combi-
nation of both.
Autophagy allows recycling of cytoplasmic constituents or
aged proteins for the maintenance of cellular homeostasis (18).
Autophagy dysfunction can lead to cellular toxicity and dis-
eases (19–21). Accumulation of abnormal protein aggregates, a
common cause of neurodegenerative diseases, can be reduced
through autophagic degradation. Defects in autophagy are
implicated in neurodegenerative disorders (22, 23). Not only
autophagy defects are detrimental, an excessive increase in
autophagy can also cause neurodegeneration.
TrkA activity has been linked to autophagy-induced cell
death. Several reports described the activation of autophagy
upon TrkA overexpression in cancer cell lines (24–29), how-
ever, as the activationof autophagy is in somecases ligand-inde-
pendent (30, 31) the physiological role of TrkA-induced
autophagy is still questionable. Another possibility is that TrkA
overexpression may saturate the lysosome pathway with toxic
outcomes. Lysosomes constitute the degradation destiny of
TrkA. Activation by NGF induces TrkA ubiquitination neces-
sary for internalization and targeting to the lysosomal pathway
for degradation (32, 33), however, how non-functional TrkA
mutants are degraded has not been studied.
In addition, no study has addressed if TrkA mutations
causing CIPA induce protein misfolding, aggregation, and
cell toxicity. In this context, we biochemically characterized
three mutations in NTRK1 causing CIPA that were identi-
fied in children with mild or absence of ID. One mutation is
described in this work for the first time. We found that dis-
tinct TrkA mutations behaved differently in terms of mis-
folding, subcellular localization, degradation pathways, and
cell toxicity.
Results
TrkA-Cys300stop a New Mutation in NTRK1 Causing
CIPA—In this paper we report the clinical history of a family
(Fig. 1A) with two members affected of CIPA: a 17-year-old
male (index case) and his 8-year-old sister. This family also
includes a non-affected sister and both parents. The index case
was diagnosed at the age of 6 with HSAN-IV, which was char-
acterized due to multiple fractures, hemarthrosis of lower
limbs, especially of the left knee, and non-infectious fever
related to high ambient temperature. At that time, he was using
a wheelchair but was able to stand alone. Strength decrease in
the lower limb (knees and ankles) was detected and the rest of
the neurologic exploration was normal (coordination, balance,
cranial pairs, tendon, and skin reflexes), except for the absence
of nociceptive sensitivity (tactile and proprioceptive sensitivi-
ties were conserved). ID was not present at the time of the
clinical history.
Blood samples were collected from all the family members
available: the two affected siblings, their healthy sister, the
father, and the mother. Genomic DNA was purified from the
blood of the 17-year-old affected male. All of the 17 exons and
intron-exon boundaries of the longest NTRK1 isoform
(NM_002529.3) were analyzed using PCR amplification of
genomic DNA from the patient followed by direct DNA
sequencing. The presence of the identified NTRK1 mutations
was subsequently investigated in the other relatives using the
same methods. Mutation screening in the index case (17-year-
old male) revealed the presence of a new mutation in homozy-
gosis in the NTRK1 gene, c.899_900delinsAA (p.Cys300*). The
presence of this mutation was subsequently investigated in
the other relatives using the same methods, confirming the
FIGURE 1.Mutations in NTRK1 used in this study. A, pedigree of the family
and results of theNTRK1 genetic analysis in CIPApatients. As indicated by the
symbols in thepedigree, individuals II-1 and II-2 are affectedbyCIPA,whereas
the parents and the sister are all carriers. The NTRK1 mutation detected in
each individual is indicated under the corresponding symbol. Electrophero-
grams demonstrating the presence of the NTRK1 point mutations. The posi-
tion of eachmutation is indicatedby anasterisk. B, themutations described in
this report are named following the recommendations from the Human
Genome Variation Society. C, location of the different mutations in the TrkA
protein is shown in a scheme of the NTRK1 gene. Exons are numbered and
shown as boxes.
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homozygous status of the affected sister and the carrier status
of the rest of the family members (Fig. 1A).
Together with C300stop, in this study we also investigated
two other mutations inNTRK1 causing CIPA, which cover dif-
ferent domains of TrkA (Fig. 1B); the mutation TrkA-
736(c.2206–2AG), which is a short in-frame deletion that
eliminates 7 residues in the kinase domain of TrkA (Fig. 1B),
which we previously described in a female child in Northern
Spain with no evidences of ID (34); and the mutation L213P
(c.637TC), a missense mutation in the extracellular domain
of TrkA originally characterized by Mardy et al. (35–38) with
mild ID with speech problems. For practical reasons, we will
refer to them as C300stop, 736, and L123P. These mutations
causing variable ID are located in different regions of the TrkA
protein (Fig. 1C) and are representative of the different types of
mutations found in CIPA, missense, deletion, and truncated
forms.
TrkA Signaling Pathways Are Impaired in All TrkA
Mutants—To study how the new mutations influence TrkA
activity, PC12nnr5 cells were transfected with plasmids encod-
ing the TrkA-wt and all TrkA mutations. PC12 cells derived
from a pheochromocytoma recapitulate neurite differentiation
and survival in the presence of NGF and constitutes a good
model of signaling and differentiation in the TrkA/NGF path-
way (39). The PC12nnr5 cell line was generated by the Greene
laboratory (40) and does not express TrkA, so it cannot differ-
entiate in the presence of NGF being a good model for testing
TrkA mutants. Two days after transfection cells were serum
starved and treated with NGF for different time points and
then, subjected to protein extraction andWestern blot analysis
(Fig. 2A). Upon transfection two TrkA bands are visible after
Western blot analysis; a lower band that reflects the TrkA that
has not completed Golgi-mediated processing of high-man-
nose N-glycans (41) (immature form of TrkA) and an upper
mature band expressed in the plasma membrane (mature form
of TrkA). It is established that the lowest band of TrkA is intra-
cellular and its activation corresponds to spontaneous
dimerization due to defective glycosylation (42). However,
exposure toNGF substantially increases the phosphorylation of
the upper TrkA band, consistent with that band protein being
in the plasma membrane that has access to NGF. Upon NGF
binding TrkA is activated by trans-phosphorylation in different
tyrosine residues (43). We used two phospho-specific antibod-
ies: one against phospho-Tyr-490, a site for Shc binding, and
another against phospho-Tyr-674/675 in the kinase activation
loop. The TrkA wild type is activated in a NGF-dependent
manner, aswe can see from the phosphorylation of the 140-kDa
band after 5 and 15 min. The mutants 736, L213P, and the
C300stop, however, are not activated byNGF and are not phos-
phorylated (Fig. 2A). In the L213P mutation, the lower band of
TrkA corresponding to intracellular TrkA is recognized by the
phospho-specific antibodies, indicating that the kinase domain
is actually functional, although TrkA-L213P is causing CIPA
due to a defective maturation process (35, 37). In the case of
TrkA-736, no phospho-reactive bands are observed, indicat-
ing that this mutation probably induces a global misfolding in
the kinase domain (see below), making the kinase activity non-
functional. C300stop has no kinase domain, and then no kinase
activity was expected but it was used as an internal control (Fig.
2A). Western blotting against total TrkA indicates that
TrkA-wt shows the bands corresponding to themature form of
TrkA, which is able to reach the plasmamembrane (presence of
the upper protein band), however, TrkA-736 and TrkA-
FIGURE 2. Inactivation of the signaling and neurite differentiationmediated by TrkAmutations. A,Western blotting of PC12nnr5 cells transfected with
the indicated constructs after stimulationwithNGF (50ng/ml) duringdifferent timepoints.B,differentiationof PC12nnr5 cells co-transfectedwithGFP and the
indicated TrkA constructs upon stimulation with NGF (50 ng/ml) during 72 h. Presence of neurites is observed in TrkA-wt (white arrows). C, percentage of
PC12nnr5 transfected with the indicated construct cells having neurites longer than the cell body.
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L213P are not able tomature and traffic correctly to the plasma
membrane (absence of the upper protein band).
To further analyze the effect of TrkA mutations in neurite
development, PC12nnr5 cells were transfected and stimulated
by NGF and the formation of neuronal-like dendrites was
examined and quantified (Fig. 2, B and C). PC12nnr5 cells
expressing TrkA-wt are able to form dendrites but not
PC12nnr5 cells transfectedwith736, L213P, orC300stop (Fig.
2, B and C). Altogether this analysis showed that all three TrkA
mutations identified inCIPApatients induce inactivation of the
TrkA receptor.
TrkA Mutants Are Retained in the ER and Do Not Traffic to
the PlasmaMembrane—Aswe noted above,Western immuno-
blotting analysis shows that TrkA-736 and TrkA-L213P
migratewith a unique protein band around 110 kDa, suggesting
an improper processing or traffic to the plasmamembrane (see
Fig. 2A). We carried out different approaches to analyze the
traffic of these mutants. First we used a surface-exposed bioti-
nylation protocol to determine whether TrkA proteins are
located at the cell surface. When expressed in HeLa cells the
TrkA-wt is labeled with biotin but not the TrkA mutants (Fig.
3A), confirming that TrkA mutants are not exposed at the cell
surface and suggesting that they have a defective traffic to the
plasma membrane. Next we analyzed if the TrkA mutants are
retained in the ER.We treated a total lysate of HeLa cells trans-
fected with TrkA-wt and the mutants with endoglycosidase-H
(Endo-H) (Fig. 3B), an enzyme that removes the glycans added
to asparagine residues during transit from the ER toGolgi appa-
ratus. As shown in Fig. 3B, the TrkA mutants are totally sensi-
tive to the Endo-H treatment as well as some pools of TrkA-wt.
As a control of deglycosylation the samples were incubated
with N-glycosidase (N in Fig. 3B), an enzyme that removes all
N-linked sugars. After treatment with N-glycosidase, a new
expected band around 80 kDa appears, corresponding to the
fully deglycosylated form of TrkA. This result suggests that all
TrkA mutants tested, but not TrkA-wt, are retained during
maturation through the ER, and do not reach the plasma
membrane.
We also analyzed the cellular localization of TrkA-wt and the
three mutants by immunofluorescence (Fig. 3C). An N-termi-
nal HA tag was introduced in TrkA constructs. We performed
the immunofluorescence using an anti-HA antibody without
permeating the cells. Only proteins in the plasma membrane
would be able to be labeled with HA antibody. A construct
encoding the fusion protein GFP-ras was used as a marker of
the plasma membrane (green fluorescence in Fig. 3C). Our
results showed that only TrkA-wt is localized in the plasma
membrane but all the TrkA mutants tested remained intracel-
lular (Fig. 3C). A control experiment in the presence of 0.1%
Triton X-100 to permeate the cells before the immunofluores-
cence showed that all constructs are equally expressed (Fig. 3C).
We next studied the intracellular localization of TrkA-wt
and TrkA mutants. We used two protein markers: calnexin, an
ER resident transmembrane protein, and giantin a Golgi
marker (Fig. 4). We used the Pearson’s coefficient to assess co-
localization of TrkAwith calnexin (Fig. 4B) or giantin (Fig. 4D).
Using this analysis we found that the three TrkA mutants are
significantly co-localized with calnexin in comparison to
FIGURE 3. TrkA CIPA mutants have impaired traffic to the plasma membrane. A, biotinylation protocol. Avidin-HRP immunodetection of TrkA immuno-
precipitates fromHeLa cells transfectedwith TrkA-wt and TrkAmutants.Mock indicates HeLa cells transfectedwith empty control plasmid. B,Western blotting
of lysates from cells transfected with TrkA-wt and TrkA mutants treated with buffer (c), End-H (H), and N-glycosidase (N). C, immunolocalization of HeLa cells
co-transfected with TrkA mutants (red) and GFP-Ras (green) in the absence and presence of 0.1% Triton X-100. DAPI nuclear staining and merge of three
channels are shown.WB, Western blot.
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TrkA-wt (Fig. 4,A andB). In addition, all themutant constructs
showed a poor co-localization with giantin, the Golgi marker
(Fig. 4, C and D). These results indicate that the TrkA mutants
are retained in the ER, although some pools of C300stop may
reach some regions of the Golgi (Fig. 4D).
For the case of TrkA-wt we observed that TrkA-wt overex-
pression inducesGolgi fragmentation (Fig. 4C), supporting ear-
lier reports (41). In this case the co-localization analysis is dif-
ficult. Although analyzed in the whole cell most of TrkA-wt is
not co-localized with giantin (Fig. 4D), some TrkA-wt pools
showed evidence of co-localization with giantin (yellow dots in
Fig. 4C) promoting the Golgi fragmentation by autoactivation
of TrkA, as previously reported (41).
CIPA Mutations Induce TrkA Misfolding and Protein
Aggregation—ER retention is usually caused by proteinmisfold-
ing. To prove misfolding we incubated a Triton X-100-soluble
fraction of TrkA-wt and the mutants with an increasing con-
centrations of trypsin. The sensitivity to trypsin digestion is
indicative of local or global misfolding. TrkA-wt digestion with
trypsin is shown in Fig. 5A. We observed that all mutations
induced a different protein band pattern in SDS-PAGE in com-
parison to the TrkA-wt. This indicates a different accessibility
to the protease digestion suggesting a local or global misfolding
(Fig. 5A).
Protein misfolding may induce the exposition of hydropho-
bic residues to the protein surface promoting protein aggrega-
tion. We evaluated if the mutations on TrkA promote the for-
mation of insoluble aggregates (44). Transfected HeLa cells
with the different TrkA constructs were lysed with buffer con-
taining the non-ionic detergent TritonX-100, and after centrif-
ugation the pellet was treated with SDS-PAGE buffer contain-
ing 1% SDS and -mercaptoethanol (Fig. 5B). TrkA-736 and
TrkA-C300stop are recovered in theTritonX-100-soluble frac-
tion (Fig. 5B). However, TrkA-L213P is mainly found in the
pellet, suggesting an aggregated state (Fig. 5, B and C). Due to
Leu-213 residue localization in the middle of a -sheet in the
TrkA extracellular domain, the L213P mutation probably
induces a structural change in that region and a subsequent
aberrant aggregation of TrkA. The L213P mutation will proba-
bly induce a structural change in that region, potentially induc-
ing an aberrant aggregation of TrkA. Some minor forms of
TrkA-wt were also found in the aggregated pellet, suggesting
the existence of off-pathways in the folding of TrkA when
overexpressed.
TrkAMutants Are Differentially Sensitive to Proteasome and
Autophagy Inhibitors—Misfolded proteins retained in the ER
are targeted to degradation by an ER quality control (11). We
determined the half-life times of themutant proteins by a cyclo-
FIGURE4.TrkACIPAmutantsare retained in theER.A,TrkAmutants (red) co-localizationwith calnexin (green) in transfectedHeLa cells. DAPI nuclear staining
and merge of three channels are shown. B, Pearson’s coefficient to assess the co-localization of TrkA-wt and mutants with calnexin. C, TrkA mutants (red)
co-localizationwithgiantin (green) in transfectedHeLa cells. DAPI nuclear stainingandmergeof three channels are shown.D,Pearson’s coefficient to assess the
co-localization of TrkA-wt and mutants with giantin. Error bars are S.E.; *, p 0.05; **, p 0.01; ***, p 0.001. t test compared with wt.
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heximide chase experiment (Fig. 6A). We found that TrkA-
L213P (t1⁄2  26 h) is degraded to a slower rate than TrkA-wt
(t1⁄2 4.5 h) suggesting a long-lived protein, probably due to the
formation of aggregates. TrkA-C300stop (t1⁄2  0.7 h) is
degraded faster than TrkA-wt, indicating a very unstable con-
former (Fig. 6B) and TrkA-736 (t1⁄2  6.5 h) is degraded to a
similar rate as TrkA-wt (Fig. 6B). We then tested the degrada-
tion pathways of TrkA mutants using inhibitors of the protea-
some or the autophagy (Fig. 6C). HeLa cells were transfected
with the constructs that encode the differentmutant TrkA, and
treated with: epoxomycin, a proteasome inhibitor; wortman-
nin, an inhibitor of autophagosome formation; rapamycin, an
inducer of autophagy; or compound E, an inhibitor of the
-secretase complex (Fig. 6, C and D). All TrkA constructs
showed resistance to degradation in the presence of wortman-
nin, indicating they are degraded mainly by the autophagy/lys-
osome pathway (Fig. 6, C and D). However, epoxomycin had a
significant effect in the accumulation of the mutant TrkA-
736, suggesting that some pools of this mutant are also
degraded by the proteasome. TrkA-L213P is a long-lived pro-
tein and even after 9 h some pools were still present implying a
resistance of this construct to be degraded or a dysfunction of
the degradation pathways in these cells.
TrkA-L213PEnhance the Formation of Autophagic Vesicles—
HeLa cells were transfected with the TrkA mutants and with a
plasmid encoding the fusion between microtubule-associated
protein light chain 3 (LC3) and GFP, LC3-GFP, to evaluate the
formation of autophagosome vesicles (AVs). Green fluorescent
AVswere observed in the cells from all constructs (Fig. 7A).We
did not observe a significant difference in the number of
autophagosomesbetweenTrkA-wtand736andC300stopcon-
structs (Fig. 7B). However, we observed a significant increase in
the number of GFP-positive AVs into the cells transfected with
L213P (Fig. 7, A and B). The presence of large and abundant
autophagosomes could be caused by a disruption of the
autophagy flux, due to enhanced autophagosome synthesis or
reduced autophagosome turnover (45). To test if L213P is influ-
encing the autophagic flux we co-transfected HeLa cells with
L213P and LC3-GFP and stimulated them with wortmannin,
which prevents autophagosome formation, and with Bafilomy-
cin A1 (BafA1), which inhibits the fusion between lysosomes
and the autophagosome (Fig. 7C). Wortmannin treatment sig-
nificantly reduced the number of AVs (Fig. 7,C andD), suggest-
ing an efficient degradation of the AVs in L213P-transfected
cells. This together with the observation that BafA1 induces the
accumulation ofmoreAVs (Fig. 7,C andD) suggests that L213P
is not disrupting the degradation of the autolysosomes per se
but that L213P enhances the formation of AVs disrupting the
FIGURE 5. TrkA CIPA mutations induce protein misfolding and aggrega-
tion. A, trypsin digestion of Triton X-100-soluble fractions of TrkA mutants.
Samples were incubated with the indicated concentrations of trypsin during
10min on ice, quenchedby adding SDS-PAGE sample buffer (2 times), boiled,
and analyzed by SDS-PAGE/immunoblot with a specific antibody against the
extracellular region of TrkA. B, analysis of disease protein solubility in the
non-ionic detergent Triton X-100. Cell extracts were prepared in lysis buffer
supplementedwith 1%Triton X-100. Total, pellet, and supernatantwere ana-
lyzed by SDS-PAGE and immunoblotting. C, the ratio of pellet to total (pellet/
total) was quantified for two independent experiments. Error bars are S.E.WB,
Western blot.
FIGURE 6.TrkA constructs havedifferent degradationkinetics anddiffer-
ential sensitivity to proteasome and lysosome inhibitors. A, Western
immunoblots of a representative experiment showing the levels of TrkA after
protein translation inhibition with cycloheximide during the indicated time
points. B, protein turnover half-lives of TrkA mutants were determined by
quantifying the remaining levels of TrkA protein normalized to the actin blot.
Three independent experiments consisting of independent transfections
were performed. Data pointswere adjusted to a one exponential decay curve
(black line) using GraphPad Prism software to calculate the half-lives times of
each TrkA construct. C,Western blot analysis of cycloheximide treatment for
9 h and the sensitivity of the different TrkA constructs to the indicated inhib-
itors. D, fraction of the total protein remaining after 9 h. The values were
normalized to time 0 h (1.0). Quantification of at least three independent
experiments was quantified. Errors bars are S.E. p values are shown on the
graph. t test compared with the control (). ns, not significant.
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normal autophagy flux saturating their degradation and leading
to an aberrant accumulation of AVs in the L213P cells.
TrkA Mutants Causing CIPA Induce Different Levels of Cell
Toxicity—Given that a delayed degradation, an accumulation of
misfolded proteins in the ER, and disruption of the autophagic
flux can trigger cell toxicity, we examined whether the expres-
sion of TrkA mutants induced cell toxicity (Fig. 8). To evaluate
this possibility we first transfected PC12nnr5 cells with all the
TrkA constructs and quantified cell death. To increase ER
stress and further challenge the cells, we added 2g/ml of tuni-
camycin. Tunicamycin induces ER stress by blocking glycosyl-
ation and ER retention. The addition of tunicamycin induces a
faster migration in the SDS-PAGE of all TrkA constructs, indi-
cating impairment in the glycosylation pathway (Fig. 8A). Cell
death assays analyzed by flow cytometry revealed that TrkA-
L213P and, to a lower extent, TrkA-736, mutations increased
basal cell toxicity, compared with cells transfected with con-
structs encoding TrkA-wt and TrkA-C300stop (Fig. 8B). The
presence of tunicamycin significantly increased cell death
caused by the expression of TrkA-L213P (p 0.015, n 3) and
TrkA-736 (p  0.003, n  3) (Fig. 8B). These results suggest
that TrkAmutations causing CIPA differently increase the tox-
icity and vulnerability of cells to ER stress-induced cell death,
pointing to mutation-specific cell toxicity.
TrkACIPAMutations InduceDystrophic Neurites in Cortical
Neurons—Autophagy has been reported to protect the neurons
by eliminating dysfunctional organelles and aged aggregated
proteins. We co-transfected TrkA-wt and L213P with LC3-
GFP in mouse embryonic cortical neurons (E16–E17) and
assessed for the presence of AVs (Fig. 9A). We found the pres-
ence of AVs in the dendrites and in the soma of neurons trans-
fected with L213Pmutant (Fig. 9A) but not in neurons express-
ing TrkA-wt (Fig. 9A). This supports the role of TrkA-L213P in
enhancing the autophagy inducing an accumulation of AVs
that may underlay neuronal toxicity.
We then co-transfected mouse embryonic cortical neurons
with TrkA-wt and TrkA-L213P together with a vector encod-
ing GFP. 48 h after transfection we noticed the presence of
swelling neurites in the neurons expressing L213P and not in
TrkA-wt (Fig. 9,B andC). Swollen neurites have been described
as a sign of neurodegeneration and synaptic loss is some neu-
rodegenerative diseases (46). Altogether this indicates that
FIGURE 7. TrkA CIPA mutants induce the autophagic flux. A, HeLa cells were co-transfected with mock vector and the indicated TrkA constructs with
LC3-GFP. A composite of confocalmicroscopy images for the channelgreen (LC3-GFP) and red (TrkA) is shown.B, thepresenceof greenpuncta indicativeofAVs
was quantified and plotted as the number of AVs per cell. C,HeLa cells co-transfectedwith TrkA-L213P and LC3-GFPweremock, wortmannin, and bafilomycin
stimulated for 6 h, fixed, and analyzed by confocal microscopy. The number of green puncta of at least 20 cells was plotted in D. Error bars are S.E. *, p 0.05;
** p 0.01; ***, p 0.001. One-way analysis of variance test with Tukey’s multiple comparisons test (B) and t test (D) was compared with control.
FIGURE 8. Cell toxicity of TrkA CIPA mutations in PC12nnr5 cells. Tunica-
mycin induces inhibition of protein glycosylation of all TrkAmutants.A,West-
ern immunoblotting showing a decrease in themolecularweight due to inhi-
bition of N-glycosylation of all the TrkA constructs upon tunicamycin
treatment. B, percentage of PC12nnr5-transfected cells experimenting cell
death (apoptotic cells) quantified by annexin V/propidium iodide. 2g/ml of
tunicamycin were added to increase the basal ER stress. Three independent
experiments were quantified. Error bars are S.E. p values are shown on the
graph. t test compared with the control (C) is shown. ns, not significant.
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TrkA-L213P induce an increase in the formation of autophago-
somes that causes cell toxicity and dystrophofic neurites in
neurons.
Discussion
In thisworkwe characterize threemutations inTrkAcausing
CIPA. We analyzed the subcellular localization, degradation
half-live times, misfolding, aggregation, and cellular toxicity in
cells and in primary culture of neurons. Our data suggest that
distinct TrkA mutations causing CIPA induce different con-
formerswith different fates and toxicities. The newCIPAmuta-
tion TrkA-C300stop forms soluble misfolded conformers that
are rapidly cleared by autophagy. When overexpressed in neu-
rons TrkA-C300stop induces mild toxic effects. TrkA-L213P
mutation induces TrkA misfolding, and retention in the ER.
Some pools of TrkA-L213P form Triton X-100-insoluble
aggregates and a delayed degradation. When expressed in cells
this mutant significantly increased the formation of autophagic
vesicles inducing swollen regions in neurons and sensitized
PC12nnr5 cells to cell death induced by tunicamycin. The
mutant TrkA-736 shows an intermediate phenotype between
C300stop and L213P.
Misfolding could potentially affect not only the specific func-
tion of the protein but it could also lead to aggregation and
toxicity. Accumulation of misfolded proteins in the ER is
known to induce ER stress, which has also been implicated in
humandisease, including several neurodegenerative conditions
(47–49). Our data suggest that some TrkA mutations increase
the autopahgic flux and this promotes toxicity andneurodegen-
eration. Disruption of the autophagy homeostasis can lead to
cellular dysfunction and diseases. Moreover, excessively dereg-
ulated autophagy can also cause neurodegeneration. In CIPA
the absence of pain sensation is due to the lack of nociceptors
neurons by disruption of TrkA/NGF signaling during embry-
onic development. However, the molecular mechanism by
which CIPA patients present intellectual disability, a problem
that must be localized in the central nervous system, is still
unknown. TrkA is expressed in the cholinergic neurons from
the basal forebrain during brain development and in adulthood
and probably in other neuron populations of the CNS. As TrkA
mutations induce different levels of cell toxicity, we suggest
they may play a role in exacerbating some of the symptoms of
CIPA patients in the central nervous system like mental
retardation.
We think that depending of the type of mutation in TrkA, a
higher or lower toxicity is induced in the population of neurons
that expressed TrkA in the CNS and this may provide an expla-
nation to the variable mental retardation or ID seen in CIPA
patients. The patient with the mutation C300stop described
here has CIPA but according to his clinical history is mentally
healthy. The mutation 736 was described by our group (Dr.
Garcia-Barcina) in a girl that at that time (2011) was mentally
healthy, but because our study suggest that 736 induce some
toxicity in neurons a follow-up of her cognitive abilities are
needed to validate if some neurodegenerationwill appear in the
future. TrkA-L213P was first described in 2001 in a boy but no
clinical data about hismental statuswas reported (35, 36, 50). In
2003 another boy with CIPA carrying the same mutation,
L213P, was diagnosed with speech problems indicative of mild
ID (38), which agrees with a stronger toxicity in the neurons
expressing L213P.
In addition, our data suggest that the expression of toxic
aggregates of TrkA in the neurons could be detrimental to its
survival or could sensitize them to a neurodegenerative process
promoted by normal aging. Recently a study in Arab-Bedouins
children addressed the ID issue in CIPA (51). A cohort of 22
children (2–21 years old) with CIPA, carrying the same TrkA
mutation (1926-ins-T) and 19 age-matched healthy children
were assessed and documented for cognitive and adaptive
behaviors (51). The results showed an inverse correlation
between intelligent quotient (IQ) and age among children with
CIPA; the older the child with CIPA, the lower the IQ score
deterioration. We think this may reflect a neurodegenerative
process in the CNS caused by the TrkA mutation during brain
maturation. However, an analysis with more mutations and a
standardized value of ID is needed to fully validate this
hypothesis.
Finally, several works have linked TrkA activity to enhanced
autophagy and cell death (24–29). Although we used small
amounts of TrkA in our transfections, we observed that over-
expression of TrkA-wt is able to increase the autophagic flux to
levels that are toxic toHeLa cells (data not shown). This finding
is supported by early work demonstrating that TrkA-induced
FIGURE 9. Presence of AVs and dystrophic neurites in L213P-transfected
embryonic cortical neurons. A, embryonic cortical neurons were co-trans-
fected with LC3-GFP and TrkA-wt or TrkA-L213P. 24 h post-transfection neu-
rons were fixed and stained with TrkA antibody immunofluorescence (red).
Several greenpositiveAVs are observed in the somaand in theneurites of the
neurons transfected with TrkA-L213P. B, E17 embryonic mouse cortical neu-
rons were co-transfected with TrkA-wt and the CIPA mutants and GFP. Rep-
resentative transfected neurons are shown. The presence of swollen regions
in the neurites is indicated bywhite arrows. Inserts showed the TrkA staining.
C, quantification of the percentage of transfected neurons bearing swollen
regions. A positive neuron is counted if has more than 10 swollen regions in
the axonor in the neurites. Error bars are S.E. p values are shownon the graph.
t test compared with the control (C) is shown. ns, not significant.
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cell death is dose-dependent (52) and that TrkAoverexpression
is able to trigger autophagy and apoptosis in glioblastoma (26)
and in neuroblastoma cells (31), cancer cell lines where TrkA
overexpression is of good prognosis. Furthermore, in medullo-
blastoma Daoy cells overexpression of TrkA induced cell death
by micropinocytosis (28). Because in some of these systems the
autophagy is activated in a ligand independent manner (30, 31,
53) or by TrkA inactivating mutations (this study) no kinase
activity is necessary. One possibility is that TrkA protein by
itself would be a specific target for autophagy receptors and able
to nucleate the autophagosome formation. In this sense p62/
sequestosome 1, one of the best characterized autophagy recep-
tors (54), binds to TrkA and participates in TrkA degradation
(55–57).
In summary our analysis indicates that different mutations in
TrkA have different outcomes and this may provide an explana-
tion for the variable phenotype seen in the CNS of CIPA patients.
Although we do see significant differences between TrkA-wt and
TrkA-L21P phenotypes, our studies are carried out by overex-
pressing the different constructs.We consider that generation of a
mouse model of CIPA expressing endogenous levels of TrkA
mutants is necessary to validate our hypothesis.
Experimental Procedures
Cell Lines—HeLa cells, a cell line derived from humans, were
cultured in DMEM (Gibco) containing 10% fetal calf serum
(ThermoFisher). PC12 and PC12nnr5 cells were cultured in
DMEM with 10% FBS and 5% horse serum. All cell lines were
cultured at 37 °C in a humidified atmosphere with 5% of CO2.
Identification of the New NTRK1 Mutation pCys300stop—
Written informed consent was obtained from the patient and
all family members participating in this study. This research
work was approved by the Ethical Committee of Basurto Uni-
versity Hospital, conforming to Helsinki Declaration. Blood
samples were collected from all the family members available.
GenomicDNAwas purified using a standard “salting-out” puri-
fication protocol and its quality was assessed using a spectro-
photometer. Mutation screening was performed in the index
case. Primers for PCR amplification were designed for all 17
exons and intron-exon boundaries of the longest NTRK1 iso-
form (NM_002529.3) using the Primer3 on-line application.
Primer sequences and optimal annealing temperature for each
primer pair are available upon request. All PCR were carried
out using TaqGold DNA polymerase (Applied Biosystems)
with 5% DMSO (Sigma). Direct sequencing of both strands of
the amplified DNA fragments was performed using BigDye
Terminator version 3.1 Sequencing kit (Applied Biosystems).
Sequencing reactions were resolved on ABI PRISM 3130
Genetic Analyzer and analyzed using Sequence Scanner soft-
ware (Applied Biosystems). The mutations described in this
report are named following the recommendations from the
Human Genome Variation Society.
In Vitro Site-directed Mutagenesis—To generate the con-
structs of the TrkAmutants a pair of selected oligonucleotides
for each mutation was purchased from Sigma and the
QuikChange mutagenesis kit (Agilent) was used following the
commercial guidelines. Sequences of the oligonucleotides are
as follows. For TrkA L213P, TrkA-L213Pfw, 5-GGGGGATG-
ACGTTTTTCCGCAGTGCCAGGTGGAGG-3 and TrkA-
L213P-rev, 5-CCTCCACCTGGCACTGCGGAAAAACGT-
CATCCCCC-3. For TrkA-C300STOP, a stop codon was
introduced after the positionCys-300 of TrkA using the follow-
ing pair of oligonucleotides; TrkA-C300fw, 5-GGTGGA-
GATGCACCACTGGTAAATCCCCTTCTCTGTGG-3 and
TrkA-c300-rev, 5-CCACAGAGAAGGGGATTTACCAGT-
GGTGCATCTCCACC-3. For TrkA-736, a deletion of
seven residues in-frame was created using the following pair
of oligonucleotides: TrkA-del736fw, 5-TGGTACCAGCT-
CTCCAACACTGAGGGCCGGGAGCTGGAGCGG-3 and
TrkA-del736-rev, 5-CCGCTCCAGCTCCCGGCCCTCA-
GTGTTGGAGAGCTGGTACCA-3. The plasmid DNAwas
sequenced using the local genomic facilities of ISCIII.
Stimulation of Cells with NGF—Themutant or the wild-type
TrkA-transfected cells and mock-transfected cells as well as non-
transfected cells were treated under the same conditions in a six-
well tissue culture plate. The cells were washed three times with
serum-free medium and incubated for 2 h in a serum-free
medium.After themediumwasaspirated, 1mlof fresh serum-free
medium containing 50 ng of NGF (Alomone) was followed by
incubationat37 °Cat thedifferent timepoints.Thecellswere then
immediately washed three times with phosphate-buffered saline
and lysedusingTNEbuffer (Tris-HCl, pH7.5, 150mMNaCl, 1mM
EDTA) supplementedwithTritonX-100 (Sigma) andamixtureof
protease inhibitors (RocheApplied Science) and phosphatase-like
sodium orthovanadate (Na3VO4, Sigma) and sodium fluoride
(NaF) (Sigma). Cellswere harvested by scraping, transferred into a
1.5-ml tube, and collected by centrifuging at 12,000 g for 5 min
in a microcentrifuge. Supernatant was analyzed by SDS-PAGE or
processed as indicated.
Immunoblotting—Primary antibodies used were as follows: a
rabbit polyclonal antibody against TrkA (dilution 1:3000,
06-574 from Millipore) and two phospho-specific antibodies
(TrkA(Tyr-490) 4619, dilution 1:1000, and TrkA(Tyr-674/675)
4621 dilution 1:1000 fromCell Signaling). Polyclonal anti-TrkA
was used to directly detect total TrkA protein. The latter two
phospho-specific antibodieswere prepared todetect phosphor-
ylated Tyr-490 and Tyr-674/675 residues. The membrane was
incubated with the primary antibody diluted in TBS 	 0.1%
Tween 20 (Sigma) overnight at 4 °C. For detection we used ECL
Western blotting detection reagents (Amersham Biosciences)
and exposure to x-ray film.
Trypsin Digestion and Triton X-100 Solubility Assay—Cell
pellets were lysed for 1 h at 4 °C in TNE buffer supplemented
with 1% Triton X-100, pH 7.5. Protein concentrations of
lysate were determined using the Bradford assay (Bio-Rad)
and normalized across all samples. An aliquot of lysate was
removed for the trypsin digestion assay. The remaining
lysate was subjected to centrifugation at 20,000  g for 15
min at 4 °C. Supernatant was removed and added to 67 l of
4 SDS-sample buffer with 1.25% -mercaptoethanol. Pel-
let was solubilized with the same volume of 2 SDS-sample
buffer with 1.25% -mercaptoethanol.
Trypsin digestion assays were performed by incubating the
soluble lysate with three increasing concentrations of trypsin in
PBS and on ice for 5 min. The reaction was stopped by adding
2 SDS-PAGE sample buffer and boiled for 10 min.
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Cell Surface Biotinylation Assay—Transfected cells with the
indicated TrkA constructs were washed sequentially using
room temperature PBS and cold PBS, chilled on ice, and incu-
bated in 0.5g/ml of Sulfo-NHS-SS-biotin (Pierce) dissolved in
biotinylation buffer (PBS, 1 mM CaCl2, 0.5 mM MgCl2) for 20
min at 4 °C to label the membrane proteins. Free biotin was
quenched with 0.1 M glycine for 15 min at 4 °C. Cells were then
washed twice with cold PBS and lysed as indicated above. Bioti-
nylated proteins were isolated from the total cell lysate by
immobilization on NeutroAvidin beads (Pierce) overnight at
4 °C. Beads were washed three times with lysis buffer and 20 l
of 2 SDS sample buffer was added before boiling for 7 min.
Proteins were subjected to SDS-PAGE and immunoblotted
with HA antibodies to detect TrkA.
Cycloheximide Treatment and Half-life Calculations—HeLa
cells were transfectedwith 1g of empty vector (control) or the
indicatedTrkAmutants. 48 h post-transfection, cells in a 6-well
platewere incubatedwith 5g/ml of cycloheximide in the pres-
ence and absence of 15 M chloroquine or 10 M epoxomycin.
Cells were harvested in TNE lysis buffer t  0, 1, 4, and 9 h
post-cycloheximide. The half-lives were calculated using the
values obtained from densitometry of Western blots using
ImageQuant (Molecular Dynamics) software. Values were fit to
the half-life decay equation using GraphPad Prism software to
an exponential regression of the form:N(t)N(0 h) et.  is
the decay constant. Half-lives (t1⁄2) were calculated using the
equation t1⁄2 ln(2)/.
Confocal Microscopy—HeLa cells were grown and trans-
fected on sterile coverslips. Thirty-six h post-transfection, cov-
erslips were removed from media and fixed with 4% parafor-
maldehyde. Coverslips were washed 3 times in PBS, and 100 l
of blocking buffer (PBS with 1% FBS) were added on coverslips
for 1 h. Blocking bufferwas aspirated and replacedwith primary
antibody (rabbit anti-calnexin C5C9, number 2679 from Cell
Signaling, dilution 1:500; rabbit anti-giantin number ab80864
from Abcam, dilution 1:1000; and mouse anti-HA antibody
numberH3663 fromSigma, dilution 1:2000) diluted in blocking
buffer for 1 h. Primary antibody was then aspirated, coverslips
were washed three times, and secondary antibody (anti-mouse
Ig Alexa 555, number A31570 Invitrogen, anti-rabbit Ig Alexa
488 number A21206, Invitrogen) diluted in blocking buffer
withDAPI stainwas added.After 1 h, the solutionwas aspirated
and coverslips werewashed three timeswith PBS, andmounted
onto slides usingmountingmedia. Slides were allowed to dry in
the dark at room temperature for at least 12 h before imaging.
Cells were imaged using a Leica SP5 spectral confocal micro-
scope. Pearson’s coefficient of co-localization was calculated
using Leica software with at least five different cells from each
experiment.
Cell Viability and Apoptosis Assay—PC12nnr5 were trans-
fected with the indicated constructs. 48 h after transfection,
cells were lifted in PBS and analyzed by annexin V/propidium
iodide apoptosis assay by flow cytometry. Propidium iodide and
annexin V-FITC were used to discriminate between apoptotic
and necrotic cells. According to the manufacturer’s instruc-
tions, cells were incubated with the reagent for 20 min at room
temperature in the dark and then analyzed via flow cytometry
using a MACSQuant Analyzer cytometer (Miltenyi Biotec).
Embryonic Cortical Neurons Culture Methods—E16–E17
mice cortex was dissected. Briefly whole cortices from three
embryos were collected in a Petri dish containing Hanks’ bal-
anced salt solution. After carefully removing the meninges, the
tissue was divided into cortical hemispheres, dissected, and the
non-cortical structures were removed. Then cortical tissue was
digested in 1 ml of 2.5 mg/ml of trypsin and 0.5 ml of 200
units/ml of DNase I, incubated for 10 min at 37 °C and turned
twice. The supernatant was removed and after that, the pellet
was suspended in 0.5 ml of 4% BSA, 1 ml of NB/B-27. The
solutions must be cold all the time. The tissue was disaggre-
gated with a pipette until tissue was completely dispersed. 2.5
ml of 4% BSA was added in the bottom of the tube and the
dissociated cell suspensionwas centrifuged at 200 g for 5min.
The supernatant was replaced with 5 ml of 0.2% BSA in PBS.
The cell suspension was passed through a 40-m nylon filter.
Viable cells were counted using trypan blue. After cells were
counted, cells suspension was centrifuged again at 200 g for 5
min and the supernatant replaced with plating medium (NB
mediumwith B-27 supplement and 2mM L-glutamine and 0.5%
penicillin-streptomycin). Isolated cells were seeded onto cover
slides of 24-well plates pre-coated with poly-D-lysine (100
g/ml) and laminin (5 g/ml) at a density of 250,000 cells/well
(2  105 cell/cm3). Neurons were allowed to adhere and
recover. On the second day, half of the medium was replaced
with fresh NB, B27, and 2 M AraC. 4 days after, the cells were
transfected.
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